Despite many VC funds failing to return money to their investors, Swiss VC firm Redalpine has stood out as an exception. The firm’s strong performance has led to its newly announced $200 million seventh early-stage fund being oversubscribed.
Known as Redalpine Capital VII (RAC VII), the fund is already actively supporting 15 to 20 European early-stage companies, with investments in ventures like German nuclear startup Proxima Fusion.
According to founding partner Michael Sidler, the fund has already completed its first close and begun deploying capital, with plans to open an office in London. The firm’s track record of consistent top quartile returns has been a key factor in attracting fresh funding.
With over $1 billion in assets under management and a focus on European deep tech, Redalpine has built a strong network of limited partners who have seen impressive returns on their investments. This has allowed the firm to secure continued support and investment.
Redalpine remains sector-agnostic, targeting innovation in a variety of sectors including energy, health, and food. This broad scope has helped the firm navigate market volatility and achieve successful exits even in challenging market conditions.
Led by professionals with scientific and engineering backgrounds, Redalpine is able to engage with scientific founders on a deep level and provide operational support to portfolio companies. The firm’s international presence in Silicon Valley, Berlin, Zurich, and soon London, allows it to tap into diverse ecosystems for promising investment opportunities.
One such opportunity is U.K.-based ExpressionEdits, a computational gene editing platform backed by RAC VII. Through leveraging AI technology, the company aims to revolutionize cell and gene therapy, reflecting the intersection of AI and biotechnology driving technological advancements today.
